Editor’s pick: Indapta Therapeutics
Science & Technology

Editor’s pick: Indapta Therapeutics

Technology tamfitronics Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Indapta Therapeutics is using a subset of natural killer cells found in healthy donors to supercharge monoclonal antibodies to fight cancer and autoimmune disease. Natural killer (NK) cells, the cytotoxic effector cells of the innate immune system, are attractive candidates for immunotherapy because of their ability to generally recognize and kill stressed cells, such as tumor cells and virus-infected cells. However, some NK cells are better killers than others, depending on their specific repertoire of inhibitory and activating receptors that bind to respective ligands on target cells. Indapta Therapeutics aims to harness the power of a subset of...
Continue reading
Top Stories

Media24 editors were unaware of possible newspaper closures

Top Stories Tamfitronics Editors of newspaper titles facing possible closure did not know their company, Media24, was weighing its options about these titles, according to several senior editorial staff members.“We are reeling from shock. The idea that we could be unemployed before the end of the year hit home. That our CEO could not say to those writing about the impending closure that they would not shut us down hit a nerve,” said one of the editors.Moneyweb reported on Thursday that Media24 was considering shutting down the print versions of City Press, Rapport, Beeld and Daily Sun in October. “Four sources at the media company have independently confirmed a decision has been taken to close them,” said the report. Davidson said the report...
Continue reading